Patients with Systemic lupus erythematosus (SLE) experience various peripheral and central nervous system manifestations including spatial memory impairment. A subset of autoantibodies (DNRAbs) cross-react with the GluN2A and GluN2B subunits of the NMDA receptor (NMDAR). We find that these DNRAbs act as positive allosteric modulators on NMDARs with GluN2A-containing NMDARs, even those containing a single GluN2A subunit, exhibiting a much greater sensitivity to DNRAbs than those with exclusively GluN2B. Accordingly, GluN2A-specific antagonists provide greater protection from DNRAb-mediated neuronal cell death than GluN2B antagonists. Using transgenic mice to perturb expression of either GluN2A or GluN2B in vivo, we find that DNRAb-mediated disruption of spatial memory characterized by early neuronal cell death and subsequent microglia-dependent pathologies requires GluN2Acontaining NMDARs. Our results indicate that GluN2A-specific antagonists or negative allosteric modulators are strong candidates to treat SLE patients with nervous system dysfunction.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of autoantibodies directed against multiple self-antigens, including DNA 1 . These autoantibodies affect multiple organ systems such that SLE patients experience arthritis, renal disease, anemia, rashes, and neuropsychiatric symptoms including memory disorders and spatial memory impairment 2, 3, 4 . The prevalence of diffuse nervous system disorders is reported from 20-90% depending on the particular functional assessment 5, 6, 7 . These cognitive defects in both clinical and pre-clinical conditions are often associated with DNRAb, anti-double stranded DNA (dsDNA) antibodies with cross-reactivity to NMDA receptors (NMDAR) 8, 9, 10, 11, 12, 13, 14 .
The role of DNRAbs in contributing to neuropsychiatric symptoms in SLE have largely been studied in mice models that endogenously synthesize DNRAbs and in mice exposed to patient-derived DNRAbs 8, 10, 11 . Patient-derived DNRAbs are IgG1 antibodies cloned from patient B cells that display reactivity to dsDNA and NMDARs 15, 16 . Specific regions of the brain in mice are targeted based on the experimental method used to trigger blood brain barrier permeability -lipopolysaccharide (LPS) causes DNRAbs to deposit in the hippocampus while epinephrine causes DNRAbs to deposit in the amygdala 11, 17 . Non-invasive imaging of SLE patients have revealed hippocampal atrophy and parahippocampal microstructural defects, conferring an advantage to using LPS in disease models 4, 18 .
LPS-treated mice immunogenized to generate DNRAbs and patient-derived DNRAbs display a gamut of pathologies in the hippocampus: aberrant excitatory signaling, apoptosis, dendritic pruning, and microglial activation 10, 11, 19 . These mice also display expanded place fields in the hippocampus and defects in spatial memory 2, 19 . These studies are essential to defining the pathology of the neuropsychiatric component of SLE, but do not define the specific NMDARs that mediate these effects. This information is critical to potentially develop therapies to treat and prevent neuropsychiatric symptoms associated with DNRAbs.
NMDARs are ionotropic glutamate receptors that are central to excitatory synaptic transmission in the brain. NMDARs are heterotetramers composed of two obligate GluN1 subunits and typically two GluN2 subunits of the same or different subtype (GluN2A, B, C or D) 20, 21 . DNRAbs bind to both GluN2A and GluN2B subunits, with the epitope including a pentapeptide consensus sequence, DWEYS 10, 11 . This antigenic target for DNRAbs is in the extracellularly located amino-terminal domain (ATD) of GluN2, an allosteric hub for modulating NMDAR function 21, 22 . NMDARs containing GluN2A or GluN2B have distinct physiological, pharmacological, and signaling properties 22 . Nevertheless, the contribution of the different GluN2 subunits to the SLE-associated neuropathologies is unclear. Knockout studies in mice have suggested GluN2A to be the primary target for DNRAb-mediated adult and fetal neuronal cell death 23 , though the evidence was limited. Specific inhibitors of GluN2B also reduced DNRAb-mediated cell death, suggesting a significant contribution of GluN2B to the DNRAbmediated phenotype 10 . All these results are ambiguous because of uncertainty of concentrations and technical limitations.
Here, we use a combination of heterologous expression systems and animal models to show subunit-specific susceptibility to DNRAb-mediated pathological effects. For heterologous expression, we tested a DNRAb (G11 and its B1 isotype control) derived from a human patient (see Materials and Methods) in concentrations relevant to patient CSF levels 10 . We find that DNRAbs act as positive allosteric modulators (PAMs) at both GluN2A-and GluN2B-containing NMDARs, but that GluN2A-containing receptors have a much higher intrinsic sensitivity to DNRAb-mediated potentiation than GluN2B-containing NMDARs. Using a heterologous expression system to express tri-heteromeric GluN1/GluN2A/GluN2B, we find that a single GluN2A subunit confers high sensitivity to DNRAbs. We find that mice with a forebrain deletion of the GluN2B subunit display the full spectrum of DNRAb-mediated pathology, including acute loss of hippocampal CA1 neurons, dendritic abnormalities in surviving neurons, microglia activation, defective place cell fields, and impaired spatial memory. Conversely, GluN2A knockout mice are protected from the effects of DNRAbs. Thus, our work identifies the GluN2A subunit as the central mediator of NMDAR-associated nervous system pathology in SLE, supporting the use of GluN2A-specific negative allosteric modulators to treat SLE patients with brain dysfunction.
RESULTS
GluN2A-containing NMDARs are significantly more sensitive to DNRAbs than GluN2Bcontaining receptors.
DNRAbs bind to both GluN2A and GluN2B subunits 2, 10 . To begin to address how these subunits contribute to DNRAb-induced phenotypes, we characterized the effect of a SLE patient-derived monoclonal DNRAb, G11, on heterologously expressed NMDARs composed of human NMDAR subunits, either hGluN1a/hGluN2A (hN1/hN2A) or hGluN1a/hGluN2B (hN1/hN2B).
In parallel with antibody titers found in SLE patient CSF samples 10 , we test the DNRAbs at concentrations from 1-100 g/ml. For macroscopic or whole cell currents, exposure of hN1/hN2A NMDARs to 10 g/ml of G11 (green traces) strongly potentiated glutamate-gated current amplitudes compared to baseline ( Figure 1A) . In contrast, a similar exposure to N2Bcontaining receptors had no effect on current amplitudes ( Figure 1B) . A matched concentration of an isotype control antibody, B1 (gray traces), had no effect on current amplitudes for either N2A-or N2B-containing receptors.
For N2A-containing receptors, current amplitudes showed significant potentiation even at 1 g/ml compared to its matched control ( Figure 1C ). In contrast, only at 100 g/ml, did N2Bcontaining receptors show significant potentiation relative to its control ( Figure 1D ). Overall, these results suggest that, in terms of receptor gating, N2A-containing receptors are about 100fold more sensitive to DNRAbs than N2B-containing receptors.
DNRAbs might potentiate NMDAR activity by acting as an agonist at the glutamate ligandbinding domain. To test this idea, we measured leak currents in the absence of glutamate in parallel to peak current amplitudes (Supplemental Table 1 ), but found that changes in leak Hence, DNRAbs by themselves do not act as NMDAR agonists.
DNRAbs act as positive allosteric modulators (PAMs)
To further verify these actions of DNRAbs, we measured single channel activity of N2A-or N2B-containing NMDARs exposed either to control antibody B1 or to G11 ( Figures 1E-1H ).
These recording were made in the on-cell configuration in the continual presence of glutamate and glycine (as well as 0.05 mM EDTA) 24 . The equilibrium open probability (eq. Popen), an index of the ease of ion channel opening, with control antibody for wild type hN1/hN2A (0.40 ± 0.07, n = 6)(mean ± SEM, n = number of patches) and hN1/hN2B (0.18 ± 0.04, n = 6) is comparable to previously published values 25 . At 10 g/ml of G11, hN1/hN2A single channel activity was significantly potentiated ( Figure 1E ) relative to the matched control ( Figure 1G ). For hN1/hN2B, we again saw no significant effect of G11 on receptor gating at 10 g/ml ( Figures 1F & 1G) . At 100 g/ml ( Figure 1G ), the weak potentiation was not significant reflecting in part the variability of single channel recordings of N2B-containing receptors. These results further indicate that N2A-containing receptors are more sensitive to DNRAbs than N2B-containing receptors. Table 2 ). Further, the frequency of opening was significantly enhanced for N2A-containing receptors ( Figure 1H ). Thus, DNRAbs act by enhancing forward rates to the open state rather than by stabilizing the open channel.
A single copy of GluN2A confers high DNRAb sensitivity to NMDARs
At native synapses, NMDARs are typically composed of GluN1 in combination with different
GluN2 subunits, often one GluN2A and one GluN2B subunit, so-called triheteromeric receptors 26, 27 . We therefore tested whole-cell currents from triheteromeric receptors, where the receptor contains a single copy of GluN2A (Figure 2A ). To generate triheteromeric receptors, we used NMDAR constructs having coiled-coiled domains that permit only specific subunit combinations to reach the plasma membrane 28 . At 10 g/ml of DNRAb, diheteromeric N2Acontaining receptors containing the coiled-coiled domains showed significant potentiation.
Diheteromeric N2B-containing receptors again showed no potentiation. In contrast, triheteromeric receptors containing a single copy of GluN2A showed significant potentiation.
Thus, a single copy of GluN2A confers high sensitivity to DNRAbs.
DNRAbs modify receptor function via the DWEYS motif
DNRAb interact and presumably alter NMDAR function through the DWEYS motif in the amino-terminal domain. To directly test this idea, we introduced a charge reversal in the middle of the GluN2A DWEYS motif (DWDYS), mutating the negatively charged aspartate (D) at (D) Single charge reversal prevents DNRAb (10 g/mL) potentiation of whole cell currents (mean ± SEM, n = 5, all conditions). (E) Left, Current records of triheteromeric (N1/N2A-N2A(D285K)) or diheteromeric (N1/N2A(D285K)-N2A(D285K)) NMDARs. Currents displayed as in Figure 1A . Right, Bar graphs (mean ± SEM) (from left to right, n = 5, 6, 5, 7, 5, 6) showing normalized current amplitude for diheteromeric NMDARs (N1/N2A-N2A or N1/N2A(D285K)-N2A(D285K)) or triheteromeric receptors (N1/N2A-N2A(D285K)) at 10 µg/mL of B1 or G11 (*p < 0.05, Mann-Whitney U test). position 285 (DWDYS) to the positively charged lysine (K) (D285K). We avoided sites possibly involved in coordinating Zn 2+ to mitigate confounding effects from Zn 2+ modulation 29, 30 .
N2A(D285K) has no apparent effect on current properties (Supplemental Table 3 ). The G11 antibody shows robust binding to NMDARs ( Figure 2B , middle images). This binding is significantly attenuated in receptors containing D285K (Figures 2B, right images, & 2C). We did not find significant differences in the intrinsic binding of GluN2A or GluN2B-specific epitopes to G11 (Supplemental Figure 1 ), suggesting that the difference in sensitivity primarily reflects gating. Receptors containing D285K are no longer significantly potentiated by DNRAbs ( Figure   2D ), indicating that binding of DNRAbs to the DWEYS motif mediates the positive allosteric effect.
We also tested whether a single (triheteromeric receptor) or two (diheteromeric receptors) copies of the charge reversal are required to disrupt function. Consistent with the results for GluN2A/GluN2B triheteromeric receptors, a single copy of wild type GluN2A confers full sensitivity to DNRAbs ( Figure 2E ). Thus, in terms of stoichiometry, binding of a single
DNRAbs to the DWEYS motif on GluN2A can generate the full positive allosteric effect.
GluN2A antagonists are neuroprotective against DNRAbs
Our results indicate that N2A-containing receptors are significantly more sensitive to DNRAbs than N2B-containing receptors. To see if attenuating N2A-activity is neuroprotective, we incubated primary hippocampal cultures either in control antibody (B1) ( Figure 2F , left images) or in G11 (10 g/mL) in the absence or presence of N2A antagonists (TCN-201 or MPX-004),
which are specific at the concentrations used here 28, 31 , or a N2B-specific negative allosteric modulator (ifenprodil) and assayed the number of DAPI positive cells associated with activated caspase-3 activity ( Figure 2G ). In the presence of DNRAb alone, apoptotic cell death was extensive, consistent with previous results 3, 8, 32 . This cell death was significantly attenuated in the presence of MPX-004. In contrast, ifenoprodil was less able to protect against cell death
. Thus, specific N2A-antagonists are neuroprotective against DNRAbmediated cell death.
Assaying the contribution of GluN2A and GluN2B NMDAR subunits to DNRAb-induced phenotype in vivo
To address how the different NMDAR subunits contribute to the DNRAb-induced phenotypes in vivo, we used transgenic mouse models, either with the GluN2A subunit knocked out (grin2A -/mice, termed 'N2A KO' henceforth) or with a conditional knockout of the GluN2B subunit (grin2B fl/fl ; CaMKII Cre mice, termed 'N2B cKO') ( Figure 3A ). We used the conditional KO due to the embryonic lethality of a full GluN2B knockout 33, 34, 35 . KO mice were immunized with a decapeptide containing the pentapeptide, DWEYS, a mimetope of dsDNA and homologous to a sequence within the GluN2A and GluN2B extracellular domains, multimerized on a polylysine backbone (MAP-DWEYS) (Supplemental Figure 2 ). Immunization of wild type mice with MAP-DWEYS induces production of DNRAbs (DNRAb+ mice) 2, 11, 36 . As a control, mice were also immunized with the polylysine backbone alone (DNRAb-mice). Two weeks following two booster immunizations, mice were given LPS to allow transient access of antibodies to the hippocampus (Supplemental Figure 2) 11, 19 .
Wild type mice, when immunized with MAP-DWEYS , show two stages of DNRAbinduced pathology (Supplemental Figure 2 Figure 2 ). DNRAb+ mice also display reduced spatial memory, presumably mimicking the phenotype in SLE patients 2, 11 . Because LPS only transiently permeabilizes the blood brain barrier 2 , the acute phase is associated with the presence of DNRAbs, whereas the chronic phase is independent of the direct presence of DNRAbs 2, 19 .
Mice lacking GluN2B show DNRAb-mediated pathology while mice lacking GluN2A are protected Initially, we assayed the effect of DNRAbs on the acute phase of the pathology, namely the induction of pyramidal neuron cell death measured one week after LPS treatment 11, 19 . For all in vivo experiments, we compare the effect in DNRAb+ mice to that in DNRAb-mice in the same genetic background. DNRAb+ mice in the N2B cKO background, which still retain GluN2A, also displayed a significant loss of hippocampal neurons ( Figures 3B & 3C) . In contrast, N2A
KO mice showed no significant loss of neurons. Hence, the loss of pyramidal neurons during the acute phase is dependent on GluN2A.
Next, we characterized the chronic phase of pathology by assaying pyramidal neuron morphology eight weeks after LPS administration ( Figures 3D-3I ). Compared to its control, GluN2B cKO mice exposed to DNRAbs exhibited a significant loss of dendritic complexity, as assayed by Sholl analysis ( Figures 3D) . In contrast, in GluN2A KO mice, DNRAbs have no significant effect on dendritic complexity ( Figure 3E ). Thus, as with acute enhanced cell death, the chronic phase of SLE pathology associated with reduced dendritic complexity is also dependent on GluN2A.
DNRAb-induced activation of microglia does not occur when GluN2A is absent
The reduced dendritic complexity occurring during the chronic phase of DNRAb-induced pathology is dependent on microglia activation 19 . We therefore characterized microglia in DNRAb+ and DNRAb-mice in the various genetic backgrounds ( Figures 3F-3I ).
For the N2B cKO background, and in comparison to its control, DNRAb+ mice showed enhanced expression of CD68 ( Figure 3F Figure 3I ), suggesting a lack or reduced microglia activation. Thus, DNRAb-induced microglia activation, which is critical in dendritic morphology changes, either directly requires GluN2A and/or is dependent on acute GluN2A-induced cell death.
GluN2A is required for DNRAb-induced changes in spatial memory
During the chronic phase of DNRAb-induced pathology, wild type mice exposed to DNRAb show impaired spatial memory and disrupted place cell properties in the CA1 region of the hippocampus (Supplemental Figure 2) 2, 11, 19 . We therefore asked whether DNRAb+ N2A KO and N2B cKO mice, 8 weeks after LPS exposure, behaved abnormally in an object-place memory (OPM) task, which tests spatial memory ( Figure 4A) 37, 38 . N2B cKO mice transiently exposed to DNRAbs performed significantly worse than its DNRAb-control in the OPM task ( Figure 4B ). This parallels to what is observed in wild type mice (Supplemental Figure 2) . In contrast, no difference in performance was detected between DNRAb+ and DNRAb-N2A KO mice. Thus, GluN2A, either directly or indirectly, is required for DNRAb-induced disruptions in spatial memory.
NMDAR-dependent spatial memory and learning is linked to hippocampal place field size 39, 40 . In wild type mice exposed to DNRAbs, place field size is aberrantly enlarged, paralleling the reduced spatial memory in SLE patients and other neurodegenerative models 2, 19, 41 . To assess neuronal functional integrity, we measured place field size in freely-moving mice by implanting tetrodes into the dorsal CA1 region (Figures 4C-4D ). As in wild type, DNRAb+ N2B cKO mice exhibited significantly larger place field sizes compared to DNRAb-N2B cKO mice ( Figure   4C ), indicating that in the absence of GluN2B, the DNRAb-induced disruption of place field size persists. In contrast, DNRAb+ and DNRAb-N2A KO mice displayed no significant differences in place field size ( Figure 4D) . Thus, the cognitive deficits associated with DNRAbs are intimately linked to GluN2A, but appear largely independent of GluN2B.
DISCUSSION
Our experiments demonstrate that the GluN2A NMDAR subunit is required for various neuropathologies associated with lupus auto-antibodies. We find that DNRAbs act as positive allosteric modulators (PAM) on NMDARs with the GluN2A subunit showing a much higher sensitivity than the GluN2B subunit (Figure 1 ). DNRAb exposure manifests in two distinct phases: First, synaptic disturbances and cell death with acute exposure, and second, a loss of dendritic complexity resulting from microglia activation that occurs even after antibody is no longer detected 10, 19 . Presumably, the higher sensitivity of GluN2A to DNRAbs facilitates cell death during acute exposure. The chronic phase, including the cognitive and memory defects similar to what is seen in SLE patients 2, 42 , are also dependent on GluN2A but it is unknown whether it is a residual consequence of excitotoxicity encountered during the acute phase or a lasting change to NMDARs that predispose neurons to microglial-dependent pruning. At low concentrations, DNRAbs would affect exclusively GluN2A-containing receptors, while at high concentrations, DNRAbs would also affect GluN2B diheteromeric receptors (Figure 1) .
Previous work has shown that the GluN2B-specific inhibitor, ifenprodil, can be neuroprotective 10 . However, this most likely reflects that tri-heteromeric GluN1/GluN2A/GluN2B NMDARs, which constitute a major portion of hippocampal synapses 26, 27 , are inhibited by ifenprodil 28 . Indeed, we find that a single copy of wild type
GluN2A confers high sensitivity to DNRAbs (Figure 2A) , a result consistent with GluN2A dominance in allosteric modulation 45, 46 .
The DWEYS-motif is located in the amino-terminal domain (ATD) clamshell hinge region ( Figures 2B-2D ). GluN2A-selective PAMs and negative allosteric modulators (NAMs) have been developed to target NMDAR hypo-or hyperfunction in disease 47, 48 . While most GluN2Aselective PAMs and NAMs target the ligand-binding domain (LBD), the ATD interacts with the LBD to mediate its allosteric action 49, 50, 51, 52 . In GluN2A/GluN2B NMDARs, the GluN2A ATD interacts more extensively with the LBD than the GluN2B ATD 45, 46 , which may underlie the higher sensitivity of GluN2A to DNRAbs. Furthermore, the DWEYS motif is proximal to binding sites for other ATD allosteric modulators. Indeed, the sensitivity to Zn 2+ , a NAM, may be modulated by SLE antibodies 32 . Nevertheless, the mechanism of action of DNRAbs to produce positive allosteric modulation and the differences in sensitivity between GluN2A and GluN2B remain unknown, but are critical to define for potential therapeutic interventions.
GluN2A contributes to both the acute and chronic phases of SLE neuropathology. While the use of GluN2A NAMs may be key to treating the neuropsychiatric symptoms of SLE, any NMDAR inhibitor may lead to undesirable side effects 20, 53, 54 . Uncovering the mechanistic details of DNRAb-NMDAR interactions during distinct pathophysiological phases will help us better develop and tailor therapeutic strategies for preventing neuropsychiatric symptoms in SLE patients before acute events occurs, and treating them during chronic phases of SLE. Stony Brook. Mice (C57BL/6) were bred in house for primary hippocampal cultures at P0-P1 and glia/astrocyte feeder layers at P2-P4.
METHODS
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SLE antibodies
G11 is an IgG1 monoclonal antibody derived from a female SLE patient's B cells with Igγ1 heavy chain and Igκ light chain composition. B1 is an isotype IgG1 control derived from the same patient 16 . G11 was cloned from a B cell binding the DWEYS peptide and B1 from a B cell that did not bind the peptide or any brain antigen. The SLE patient from whom the antibodies were derived had serum antibodies reactive to dsDNA and the DWEYS peptide 2, 4 . Immunohistochemistry Mice were anesthetized as described 19 . Brains were extracted, fixed, and transferred to 30% sucrose, blocked and sliced (40 µm 
In vitro electrophysiology
Behavioral assessment and in vivo electrophysiology
Mice (20-24 weeks) were handled for 15 min per day for 3 days before being tested behaviorally.
The object place memory (OPM) task was performed 2, 19 . The apparatus consisted of a square (40 cm) chamber 40 cm high, with the walls painted grey. Animals were familiarized to the empty chamber (3 sessions of 15 min each). For OPM testing, mice underwent the following sequence: empty chamber (10 min), home cage (10 min), sample phase in which the chamber had two objects located at the center of the NW and NE sectors (5 min), home cage (10 min), choice phase in which the chamber had the same objects but one of them was moved from NE to the center of the SE sector (5 min). The discrimination ratio was calculated during the choice phase by dividing time spent exploring the moved object minus the time spent exploring the static object by the time exploring the objects combined 2 . Data were collected and analyzed using EthoVision XT (Noldus Information Technologies).
In vivo recordings of place cells in the dorsal CA1 of the hippocampus were made 2, 19 
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Use of LPS to permealize BBB. LPS by itself produces a systemic inflammatory response and neuroinflammatory effects leading to neuronal death and microglia activation 6, 7, 8 . However, for all of our in vivo experiments, we only make comparisons between DNRAb+ (experimental) mice and DNARb-(control) mice, with both of these groups being treated with LPS. In addition, LPS permealization localizes DNRAbs more in the hippocampus and related structures than in other brain regions 2, 9 . The major region of action of DNRAbs in patients is the hippocampus and related structures 10, 11 .
